Remarkable response to PD-1 inhibitor in a patient with extensive-stage small cell lung cancer: a case report and literature review
We report a case of a 59-year-old male diagnosed with extensive-stage small cell lung cancer (SCLC). He received first-line platinum doublet chemotherapy and second-line topotecan-based regimen, but experienced disease progression after each line of therapy. He was then treated with Sintilimab, a PD...
Main Authors: | Ge Yuan, Xiangliang Liu, Xinwei Zhang, Wei Song, Jin Lu, Zhongyang Ding, Xiao Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1267606/full |
Similar Items
-
Immunotherapy in Extensive-Stage Small Cell Lung Cancer
by: Rola El Sayed, et al.
Published: (2021-10-01) -
Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer
by: Ivy Riano, et al.
Published: (2021-07-01) -
Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer
by: Lingling Li, et al.
Published: (2022-09-01) -
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
by: Barbara L. Melosky, et al.
Published: (2023-06-01) -
Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency
by: Shumin Yuan, et al.
Published: (2020-11-01)